Cellular and Molecular Immunology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 10, 2024
While
immunotherapy
with
immune
checkpoint
inhibitors
(ICIs)
has
revolutionized
the
clinical
management
of
various
malignancies,
a
large
fraction
patients
are
refractory
to
ICIs
employed
as
standalone
therapeutics,
necessitating
development
combinatorial
treatment
strategies.
Immunogenic
cell
death
(ICD)
inducers
have
attracted
considerable
interest
partners
for
ICIs,
at
least
in
part
owing
their
ability
initiate
tumor-targeting
adaptive
response.
However,
compared
either
approach
alone,
regimens
involving
ICD
and
not
always
shown
superior
activity.
Here,
we
discuss
accumulating
evidence
on
therapeutic
interactions
between
oncological
settings,
identify
key
factors
that
may
explain
discrepancies
preclinical
findings,
propose
strategies
address
existing
challenges
increase
efficacy
these
combinations
cancer.
BMJ,
Journal Year:
2024,
Volume and Issue:
unknown, P. e078876 - e078876
Published: May 28, 2024
Abstract
Objective
To
evaluate
the
efficacy
and
safety
of
tislelizumab
added
to
chemotherapy
as
first
line
(primary)
treatment
for
advanced
gastric
or
gastro-oesophageal
junction
adenocarcinoma
compared
with
placebo
plus
chemotherapy.
Design
Randomised,
double
blind,
controlled,
phase
3
study.
Setting
146
medical
centres
across
Asia,
Europe,
North
America,
between
13
December
2018
28
February
2023.
Participants
1657
patients
aged
≥18
years
human
epidermal
growth
factor
receptor
2
negative
locally
unresectable
metastatic
adenocarcinoma,
regardless
programmed
death-ligand
1
(PD-L1)
expression
status,
who
had
not
received
systemic
anticancer
therapy
disease.
Interventions
Patients
were
randomly
(1:1)
assigned
receive
either
200
mg
intravenously
every
three
weeks
in
combination
(investigator’s
choice
oxaliplatin
capecitabine,
cisplatin
5-fluorouracil)
stratified
by
region,
PD-L1
expression,
presence
absence
peritoneal
metastases,
investigator’s
Treatment
continued
until
disease
progression
unacceptable
toxicity.
Main
outcome
measures
The
primary
endpoint
was
overall
survival,
both
a
tumour
area
positivity
(TAP)
score
≥5%
all
randomised
patients.
Safety
assessed
those
at
least
one
dose
study
treatment.
Results
Of
screened
9
2021,
660
ineligible
due
meeting
eligibility
criteria,
withdrawal
consent,
adverse
events,
other
reasons.
Overall,
997
(n=501)
(n=496).
Tislelizumab
showed
statistically
significant
improvements
survival
versus
TAP
(median
17.2
months
v
12.6
months;
hazard
ratio
0.74
(95%
confidence
interval
0.59
0.94);
P=0.006
(interim
analysis))
15.0
12.9
0.80
(0.70
0.92);
P=0.001
(final
analysis)).
Grade
worse
related
events
observed
54%
(268/498)
arm
50%
(246/494)
arm.
Conclusions
provided
superior
manageable
profile
≥5%,
Trial
registration
ClinicalTrials.gov
NCT03777657
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Oct. 18, 2024
Immunotherapy
has
made
significant
strides
in
cancer
treatment,
particularly
through
immune
checkpoint
blockade
(ICB),
which
shown
notable
clinical
benefits
across
various
tumor
types.
Despite
the
transformative
impact
of
ICB
treatment
therapy,
only
a
minority
patients
exhibit
positive
response
to
it.
In
with
solid
tumors,
those
who
respond
well
typically
demonstrate
an
active
profile
referred
as
"hot"
(immune-inflamed)
phenotype.
On
other
hand,
non-responsive
may
distinct
"cold"
(immune-desert)
phenotype,
differing
from
features
tumors.
Additionally,
there
is
more
nuanced
"excluded"
positioned
between
and
categories,
known
type.
Effective
differentiation
understanding
intrinsic
factors,
characteristics,
TME,
external
factors
are
critical
for
predicting
results.
It
widely
accepted
that
therapy
exerts
profound
effect
on
limited
efficacy
against
or
"altered"
necessitating
combinations
therapeutic
modalities
enhance
cell
infiltration
into
tissue
convert
tumors
ones.
Therefore,
aligning
traits
this
review
systematically
delineates
respective
influencing
extensively
discusses
varied
approaches
drug
targets
based
assess
efficacy.
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(9), P. 2549 - 2557
Published: July 2, 2024
Recent
single-arm
studies
involving
neoadjuvant
camrelizumab,
a
PD-1
inhibitor,
plus
chemotherapy
for
resectable
locally
advanced
esophageal
squamous
cell
carcinoma
(LA-ESCC)
have
shown
promising
results.
This
multicenter,
randomized,
open-label
phase
3
trial
aimed
to
further
assess
the
efficacy
and
safety
of
camrelizumab
followed
by
adjuvant
compared
alone.
A
total
391
patients
with
thoracic
LA-ESCC
(T1b-3N1-3M0
or
T3N0M0)
were
stratified
clinical
stage
(I/II,
III
IVA)
randomized
in
1:1:1
ratio
undergo
two
cycles
therapy.
Treatments
included
albumin-bound
paclitaxel
cisplatin
(Cam+nab-TP
group;
n
=
132);
(Cam+TP
130);
(TP
129),
surgical
resection.
Both
Cam+nab-TP
Cam+TP
groups
also
received
camrelizumab.
The
dual
primary
endpoints
rate
pathological
complete
response
(pCR),
as
evaluated
blind
independent
review
committee,
event-free
survival
(EFS),
assessed
investigators.
study
reports
final
analysis
pCR
rates.
In
intention-to-treat
population,
exhibited
significantly
higher
rates
28.0%
15.4%,
respectively,
4.7%
TP
group
versus
TP:
difference
23.5%,
95%
confidence
interval
(CI)
15.1-32.0,
P
<
0.0001;
10.9%,
CI
3.7-18.1,
0.0034).
met
its
endpoint
pCR;
however,
EFS
is
not
yet
mature.
incidence
grade
≥3
treatment-related
adverse
events
during
treatment
was
34.1%
group,
29.2%
28.8%
postoperative
complication
34.2%,
38.8%
32.0%,
respectively.
Neoadjuvant
demonstrated
superior
alone
LA-ESCC,
tolerable
profile.
Chinese
Clinical
Trial
Registry
identifier:
ChiCTR2000040034
.
ESMO Open,
Journal Year:
2024,
Volume and Issue:
9(2), P. 102226 - 102226
Published: Feb. 1, 2024
•This
article
provides
ESMO
recommendations
adapted
for
the
treatment
of
GC
in
Asian
patients.•It
outlines
clinical
diagnosis,
staging,
management,
and
follow-up
patients
with
GC.•Applicability
to
availability/reimbursement
certain
tests
treatments
is
described.•The
aim
encourage
evidence-based
medicine
improve
access
state-of-the-art
cancer
care.
The
European
Society
Medical
Oncology
(ESMO)
Clinical
Practice
Guidelines
gastric
(GC),
published
late
2022
updated
Gastric
Cancer
Living
Guideline
July
2023,
were
August
according
previously
established
standard
methodology,
produce
Pan-Asian
(PAGA)
consensus
guidelines
management
GC.
presented
this
manuscript
represent
opinions
reached
by
a
panel
experts
representing
oncological
societies
China
(CSCO),
Indonesia
(ISHMO),
India
(ISMPO),
Japan
(JSMO),
Korea
(KSMO),
Malaysia
(MOS),
Philippines
(PSMO),
Singapore
(SSO),
Taiwan
(TOS)
Thailand
(TSCO),
coordinated
Japanese
(JSMO).
voting
was
based
on
scientific
evidence
independent
current
practices,
drug
restrictions
reimbursement
decisions
different
regions
represented
10
societies.
latter
are
discussed
separately
manuscript.
provide
guidance
optimisation
harmonisation
across
Asia,
drawing
provided
both
Western
trials,
whilst
respecting
differences
screening
molecular
profiling
age
stage
at
presentation.
Attention
drawn
disparity
approvals
strategies,
between
Asia.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Aug. 9, 2024
The
past
few
decades
have
witnessed
the
rise
of
immunotherapy
for
Gastrointestinal
(GI)
tract
cancers.
role
immune
checkpoint
inhibitors
(ICIs),
particularly
programmed
death
protein
1
(PD-1)
and
PD
ligand-1
antibodies,
has
become
increasingly
pivotal
in
treatment
advanced
perioperative
GI
Currently,
anti-PD-1
plus
chemotherapy
is
considered
as
first-line
regimen
unselected
gastric/gastroesophageal
junction
adenocarcinoma
(G/GEJC),
mismatch
repair
deficient
(dMMR)/microsatellite
instability-high
(MSI-H)
colorectal
cancer
(CRC),
esophageal
(EC).
In
addition,
encouraging
performance
claudin18.2-redirected
chimeric
antigen
receptor
T-cell
(CAR-T)
therapy
later-line
cancers
brings
new
hope
cell
solid
tumour
treatment.
Nevertheless,
remains
yet
precise,
researchers
are
dedicated
to
further
maximising
optimising
efficacy.
This
review
summarises
important
research,
latest
progress,
future
directions
including
EC,
G/GEJC,
CRC.
